FINWIRES · TerminalLIVE
FINWIRES

Australian Shares End Slightly Lower; Zip Posts Higher Fiscal Q3 EBTDA, Upgrades Fiscal 2026 Outlook

By

Australian shares were slightly lower at Friday's close as investors awaited potential ​US-Iran diplomacy over the weekend.

The S&P/ASX 200 Index slipped 0.1% or 8.1 points to close at 8,946.90.

US President Donald Trump announced a 10-day ceasefire between Lebanon and Israel and said talks between the US and Iran may take place over the weekend. Brent crude oil futures fell over 1% to $98.14 per barrel. Spot gold climbed nearly 1% to $4,830.82 per ounce.

On the domestic front, card activity in Australia rose 1.2% over the March quarter, with quarterly momentum subdued and slowing on the 2% average seen over the June, September, and December quarters in 2025, according to a report by Westpac. The Westpac-DataX Card Tracker Index declined 2.2 points over the three weeks to April 11.

In company news, Zip (ASX:ZIP) reported Friday fiscal third quarter cash earnings before taxes, depreciation, and amortization (EBTDA) of AU$65.1 million per share, up from AU$46 million a year earlier. The company said it upgraded its fiscal 2026 group cash EBTDA guidance to be no less than AU$260 million.

Alcoa (ASX:AAI) reported Friday first-quarter adjusted earnings of $1.40 per share, down from $2.15 a year earlier. The company expects 2026 total alumina segment production and shipments to remain unchanged from its prior projection, ranging between 9.7 million to 9.9 million metric tons, and between 11.8 million and 12 million metric tons, respectively.

Lastly, Paladin Energy (ASX:PDN) said it now expects fiscal 2026 triuranium octoxide production of between 4.5 million and 4.8 million pounds, up from previous guidance of 4 million to 4.4 million pounds, from the Langer Heinrich Mine in Namibia. Its shares reached a near two-year peak during the trading session.

Related Articles

Asia

Netwealth's FUA Net Flows in Fiscal Q4 Likely to See Seasonal Step-up, Jarden Says

Netwealth Group's (ASX:NWL) funds under administration (FUA) net flows are likely to see a seasonal step-up in the fiscal fourth quarter, which would see the fiscal 2026 outcome tracking slightly ahead of its guidance range, Jarden said in a Thursday note.It raised its earnings-per-share forecasts by 0.1% for fiscal 2026, 1.5% for fiscal 2027, and 1.6% for fiscal 2028.Jarden also flagged the risk of higher cost growth due to the enforceable undertaking, regulatory scrutiny, and recent treasury consultations.The investment firm retained its neutral recommendation on Netwealth Group and raised the price target to AU$25.70 from AU$25.35.Netwealth Group's shares gained 1% in recent Friday trade.

ASX:NWL
Asia

CDL Hospitality REIT Issues Stapled Securities as Payment of Management Fee

CDL Hospitality REIT (SGX:J85) issued 5.5 million stapled securities to its manager, H-REIT Manager and HBT Trustee-Manager as payment of management fee for 2025, according to a Friday filing with the Singapore Exchange.Nearly 5 million stapled securities were issued to the H-REIT Manager at SG$0.8199 per security as 80% payment of its performance fee for 2025.Meanwhile, 535,179 securities were issued to HBT Trustee-Manager at SG$0.8199 per security as payment of 80% of performance fee for 2025.

SGX:J85
Asia

Syntara's Myelofibrosis Drug Candidate Shows 'Significant' Commercial Potential, Euroz Hartleys Says

Syntara's (ASX:SNT) Amsulostat drug candidate has a "unique" position in the myelofibrosis landscape and "significant" commercial potential, Euroz Hartleys said in a Thursday note.Myelofibrosis is a blood cancer characterized by scar tissue formation or fibrosis in the bone marrow.Dr Adam Craig, Syntara strategic adviser and an industry leader in myelofibrosis, noted Amsulostat's mechanism targeting fibrosis, with the potential as a disease-modifying therapy, rather than just a symptomatic treatment.Craig said that Amsulostat's safety profile differs from current therapies and is unaware of any other drug taking a similar approach.Additionally, Craig said that Amsulostat's mechanism requires time for effect, as fibrosis evolves gradually. Patient responses observed at six months are complemented by a continuing improvement over time.Euroz Hartleys reaffirmed its speculative buy recommendation and AU$0.22 price target on Syntara.Syntara shares fell 1% in afternoon trade on Friday.

ASX:SNT